Immunoglobulin A Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)

Growing momentum across both established and emerging therapies is reshaping the IgA nephropathy market as physicians balance established use of RAAS and SGLT2 inhibitors with adoption of newer therapies such as Asahi Kasei’s Tarpeyo / Kinpeygo, Travere Therapeutics’ Filspari, Novartis’s Fabhalta and Vanrafia, and Otsuka Pharmaceuticals’ Voyxact. Rising activity across late-phase programs, such as Alexion’s ravulizumab, Roche’s sefaxersen, Novartis’s zigakibart, Vera Therapeutics’ atacicept, Vertex’s povetacicept, Biogen’s felzartamab, and Takeda’s mezagitamab, is increasing competitive pressure and prompting reassessment of longterm treatment planning. With multiple modalities advancing and additional launches expected within the next 10 years, nephrologists are reevaluating sequencing strategies, durability expectations, and patient allocation. Supported by insights from thought-leading nephrologists, we analyze the challenges and opportunities associated with treating this complex disease.

QUESTIONS ANSWERED

• How do physicians use current therapies to treat the disease?
• Where will Tarpeyo / Kinpeygo, Filspari, Fabhalta, Vanrafia, and Voyxact be positioned in the IgA nephropathy treatment landscape? Which emerging therapies do experts find most promising, and how will these drugs influence future prescribing patterns?
• What access and reimbursement challenges will emerging therapies face upon market entry?
• What key drivers and constraints will affect the IgA nephropathy market over the forecast period?

CONTENT HIGHLIGHTS

• Markets covered: United States, EU5, Japan
• Primary research: Country-specific interviews with thought-leading nephrologists. Survey data collected for this and other Clarivate research
• Epidemiology: Diagnosed prevalent and drug-treated cases of IgA nephropathy by country and age group
• Drug treatments: Coverage of key current and late-phase emerging therapies
• Market forecast features: 10-year, annualized, drug-level sales and patient share of key IgA nephropathy therapies through 2035, segmented by brands / generics and epidemiological subpopulations

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.